SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:liu-73069"
 

Sökning: onr:"swepub:oai:DiVA.org:liu-73069" > Heterozygosity for ...

  • Holleboom, Adriaan GDepartment of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)

Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in Man

  • Artikel/kapitelEngelska2011

Förlag, utgivningsår, omfång ...

  • Elsevier,2011
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-73069
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-73069URI
  • https://doi.org/10.1016/j.cmet.2011.11.005DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding agencies|European Union| FP6-2005-LIFESCIHEALTH-6 037631 |Fondation Leducq Transatlantic Networks of Excellence||NWO| 40-00506-98-9001 |National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health||Netherlands Organisation for Scientific Research| 021.001.035 |Netherlands Heart Foundation| 2010T082 |
  • Genome-wide association studies have identified GALNT2 as a candidate gene in lipid metabolism, but it is not known how the encoded enzyme ppGalNAc-T2, which contributes to the initiation of mucin-type O-linked glycosylation, mediates this effect. In two probands with elevated plasma high-density lipoprotein cholesterol and reduced triglycerides, we identified a mutation in GALNT2. It is shown that carriers have improved postprandial triglyceride clearance, which is likely attributable to attenuated glycosylation of apolipoprotein (apo) C-III, as observed in their plasma. This protein inhibits lipoprotein lipase (LPL), which hydrolyses plasma triglycerides. We show that an apoC-III-based peptide is a substrate for ppGalNAc-T2 while its glycosylation by the mutant enzyme is impaired. In addition, neuraminidase treatment of apoC-III which removes the sialic acids from its glycan chain decreases its potential to inhibit LPL. Combined, these data suggest that ppGalNAc-T2 can affect lipid metabolism through apoC-III glycosylation, thereby establishing GALNT2 as a lipid-modifying gene.

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Karlsson, HelenÖstergötlands Läns Landsting,Linköpings universitet,Yrkes- och miljömedicin,Hälsouniversitetet,Arbets- och miljömedicin(Swepub:liu)helka90 (författare)
  • Lin, Ruei-ShiuanSection on Biological Chemistry, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA (författare)
  • Beres, Thomas MSection on Biological Chemistry, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA (författare)
  • Sierts, Jeroen ADepartment of Experimental Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Herman, Daniel SDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA (författare)
  • Stroes, Erik S GDepartment of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Aerts, Johannes MDepartment of Medical Biochemistry, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Kastelein, John J PDepartment of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Motazacker, Mohammad MDepartment of Experimental Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Dallinga-Thie, Geesje MDepartment of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Levels, Johannes H MDepartment of Experimental Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Zwinderman, Aeilko HDepartment of Clinical Epidemiology, Biostatistics, and Bioinformatics, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Seidman, Jonathan GDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA (författare)
  • Seidman, Christine EDepartment of Genetics, Harvard Medical School, Boston, MA 02115, USA (författare)
  • Ljunggren, StefanLinköpings universitet,Yrkes- och miljömedicin,Hälsouniversitetet(Swepub:liu)stelj68 (författare)
  • Lefeber, Dirk JDepartment of Neurology, Radboud University Nijmegen Medical Center, Nijmegen 6525GA, The Netherlands (författare)
  • Morava, EvaInstitute for Genetic and Metabolic Disease, Radboud University Nijmegen Medical Center, Nijmegen 6525GA, The Netherlands (författare)
  • Wevers, Ron ADepartment of Laboratory Medicine, Radboud University Nijmegen Medical Center, Nijmegen 6525GA, The Netherlands (författare)
  • Fritz, Timothy AFood and Drug Administration, Rockville, MD 20852, USA (författare)
  • Tabak, Lawrence ASection on Biological Chemistry, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA (författare)
  • Lindahl, MatsLinköpings universitet,Yrkes- och miljömedicin,Hälsouniversitetet(Swepub:liu)matli17 (författare)
  • Hovingh, G KeesDepartment of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Kuivenhoven, Jan AlbertDepartment of Experimental Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The Netherlands (författare)
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam 1105AZ, The NetherlandsYrkes- och miljömedicin (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cell Metabolism: Elsevier14:6, s. 811-81550-41311932-7420

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy